BB
NKTR icon

BB Biotech’s Nektar Therapeutics NKTR Stock Holding History

BB Biotech’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$67.9M Buy
134,712
+42,647
+46% +$25.3M 1.71% 18
2018
Q4 		$45.4M Buy
92,065
+35,732
+63% +$21.6M 1.45% 21
2018
Q3 		$51.5M Buy
56,333
+21,333
+61% +$18.2M 1.36% 23
2018
Q2 		$25.6M Buy
+35,000
New +$40.4M 0.74% 25

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BB Biotech's NKTR Position: Q1 2019 in Review

BB Biotech increased its Nektar Therapeutics (NKTR) stake by 46% in Q1 2019, buying an estimated $25.3M and bringing the position to 134,712 shares worth $67.9M. The position accounts for 1.71% of the portfolio, ranked #18.

BB Biotech first reported a position in NKTR in Q2 2018 and has held it in 4 quarters since. 350 funds tracked by Wall St. Rank hold NKTR as of Q1 2019.

  • BB Biotech held 134,712 shares of Nektar Therapeutics worth $67.9M as of Q1 2019.
  • BB Biotech bought 42,647 Nektar Therapeutics shares in Q1 2019, an estimated $25.3M.
  • Nektar Therapeutics made up 1.71% of BB Biotech's portfolio in Q1 2019, its #18 holding.
  • BB Biotech first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 4 quarters since.
  • 350 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.